Lung adenocarcinoma (LADC) and squamous cell carcinoma (LSCC) are the most common non-small cell lung cancer histological phenotypes. Accurate diagnosis distinguishing between these two lung cancer types has clinical significance. For this study, we analyzed four Gene Expression Omnibus (GEO) datasets (GSE28571, GSE37745, GSE43580, and GSE50081). We then imported the datasets into the Gene-Cloud of Biotechnology Information online platform to identify genes differentially expressed in LADC and LSCC. We identified DSG3 (desmoglein 3), KRT5 (keratin 5), KRT6A (keratin 6A), KRT6B (keratin 6B), NKX2-1 (NK2 homeobox 1), SFTA2 (surfactant associated 2), SFTA3 (surfactant associated 3), and TMC5 (transmembrane channel-like 5) as potential biomarkers for distinguishing between LADC and LSCC. Receiver operating characteristic curve analysis suggested that KRT5 had the highest diagnostic value for discriminating between these two cancer types. Using the PrognoScan online survival analysis tool and the Kaplan-Meier Plotter, we found that high KRT6A or KRT6B levels, or low NKX2-1, SFTA3, or TMC5 levels correlated with unfavorable prognoses in LADC patients. Further studies will be needed to verify our findings in additional patient samples, and to elucidate the mechanisms of action of these potential biomarkers in non-small cell lung cancer.
INTRODUCTION
Non-small cell lung cancer (NSCLC) accounts for more than 85% of total lung cancer cases [1] , and 5-year patient survival remains low at only 15.9% [1] . The most common NSCLC histological phenotypes are lung adenocarcinoma (LADC, ~50% of patients) and lung squamous cell carcinoma (LSCC, ~40% of patients) [1] . LADC cells commonly exhibit abnormal gene expression patterns and large numbers of gene mutations [2] , and are characterized by specific biomarkers [3] [4] [5] [6] [7] and prognostic factors [8] [9] [10] that can be used to guide clinical diagnosis and treatment. LSCC cells also exhibit complex genomic alterations, including numerous gene mutations and copy number alterations [11] , and are associated with particular biomarkers [12] [13] [14] and prognostic factors [15] [16] [17] .
Accurate diagnosis of the LADC and LSCC cancer types has important significance for lung patient clinical treatment. While biomarkers that differentiate LADC from LSCC have been reported previously [18] [19] [20] [21] , additional markers would help enhance diagnostic accuracy for these intractable malignant cancers. The present study identified differentially expressed genes (DEGs) between LADC and LSCC samples using comprehensive bioinformatics analyses. We identified eight potential biomarkers for discriminating LADC and LSCC, and assessed their prognostic values. 
RESULTS

Study design
We imported four Gene Expression Omnibus (GEO) datasets (GSE28571, GSE37745, GSE43580, and GSE50081) into the Gene-Cloud of Biotechnology Information (GCBI) bioinformatics analysis platform ( Figure 1 ). We extracted LADC and LSCC gene expression information from these datasets and identified DEGs between the two cancer types. From the top 10 down-or upregulated DEGs, we identified eight as potential biomarkers for discriminating LADC and LSCC. We assessed the prognostic values of these potential biomarkers using the survival analysis tools, PrognoScan and Kaplan-Meier Plotter.
DEGs in LADC and LSCC
Using GCBI, we identified 243, 210, 118, and 101 potential DEGs from GSE28571, GSE37745, GSE43580, and GSE50081, respectively (Figure 2 Table 5), 153 from  GSE37745 (Supplementary Table 6), 81 from GSE43580  (Supplementary Table 7) and 71 from GSE50081  (Supplementary Table 8 ).
Potential biomarkers for distinguishing between LADC and LSCC
Based on expression fold changes between LADC and LSCC, we selected the top 10 downregulated and upregulated DEGs from GSE28571 (Table 1) , GSE37745 (Table 2) , GSE43580 (Table 3) , and GSE50081 (Table 4) . We identified four downregulated DEGs (desmoglein 3, DSG3; keratin 5, KRT5; keratin 6A, KRT6A; keratin 6B, KRT6B) ( Figure 3 ) and four upregulated DEGs (NK2 homeobox 1, NKX2-1; surfactant associated 2, SFTA2; surfactant associated 3, SFTA3; transmembrane channel- (Figure 4 ) that were present in all four datasets. We achieved similar results via an integrated analysis based on all four datasets together (Supplementary  Table 9 -10). We assessed these eight genes as potential biomarkers for discriminating LADC and LSCC.
Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic values of DSG3, KRT5, KRT6A, KRT6B, NKX2-1, SFTA2, SFTA3, and TMC5. The four downregulated DEGs had similar areas under the curve (AUC): 0.9188 for DSG3, 0.9386 for KRT5, 0.9333 for KRT6A, and 0.9229 for KRT6B ( Figure 5A ). The four upregulated DEGs also had similar AUCs: 0.8723 for NKX2-1, 0.8559 for SFTA2, 0.8108 for SFTA3, and 0.8442 for TMC5 ( Figure 5B ). AUC results showed that KRT5 had the highest diagnostic value for discriminating LADC and LSCC.
PrognoScan identified potential prognostic factors for LADC and LSCC patients
We assessed the prognostic values of the eight potential biomarkers using the bioinformatics analysis platform, PrognoScan. P<0.05 was considered significant in Cox regression analyses. We found that high DSG3, KRT6A, or KRT6B levels (Table 5) , or low NKX2-1, SFTA3, or TMC5 levels (Table 6 ), were associated with unfavorable prognosis in LADC patients. However, only low NKX2-1 expression was associated with unfavorable prognosis in LSCC patients (Table 6 ). We speculated that DSG3, KRT6A, KRT6B, NKX2-1, SFTA3, and TMC5 might be LADC patient prognostic factors, and NKX2-1 might be an LSCC patient prognostic factor. Because each lung cancer microarray dataset in PrognoScan contained limited cases (Table 5 
DISCUSSION
In this study, we imported four GEO datasets into the GCBI comprehensive analysis platform to extract LADC and LSCC gene expression data. We identified DEGs between LADC and LSCC samples through differential expression analysis in GCBI, and found that DSG3, KRT5, KRT6A, KRT6B, NKX2-1, SFTA2, SFTA3, and TMC5 were potential biomarkers for distinguishing the two cancer types. According to ROC analyses, KRT5 had the highest diagnostic value for discriminating LADC and LSCC. Finally, using the survival analysis platforms, PrognoScan and Kaplan-Meier Plotter, we found that high KRT6A or KRT6B, or low NKX2-1, SFTA3, or TMC5 levels correlated with unfavorable prognoses in LADC patients.
Previous studies reported that DSG3 [18, 21, 22] , KRT5 [23] , KRT6A [24] , and KRT6B [24] levels were higher in LSCC than in LADC, and that NKX2-1 [25-27], SFTA3 [21] , and TMC5 [21] levels were higher in LADC than in LSCC, suggesting that these genes were biomarkers for differentiating between LSCC and LADC. In agreement with this, our results showed that DSG3, KRT5, KRT6A, and KRT6B were downregulated in LADC compared to LSCC, and that NKX2-1, SFTA3, and TMC5 were upregulated in LADC compared to LSCC. Our study also identified SFTA2 as a novel biomarker upregulated in LADC. LSCC n=28) (A), GSE37745 (total n=210; LADC n=106; LSCC n=66) (B), GSE43580 (total n=118; LADC n=77; LSCC n=73) (C), and GSE50081 (total n=101; LADC n=128; LSCC n=43) (D). www.impactjournals.com/oncotarget The potential biomarker, NKX2-1, binds DNA damage-binding protein 1 (DDB1) and degrades checkpoint kinase 1 (CHK1) to facilitate lung adenocarcinoma progression [28] . Through modulating IKKβ/NF-κB pathway activation, NKX2-1 also modulates lung adenocarcinoma by directly regulating p53 transcription [29] . However, the molecular mechanisms by which DSG3, KRT5, KRT6A, KRT6B, SFTA2, SFTA3, and TMC5 regulate NSCLC development remain unclear. DSG3 promotes epidermoid carcinoma progression by regulating activation of protein kinase C-dependent Ezrin and activator protein 1 [30] . KRT5 combines with transforming growth factor beta receptor 3 (TGFBR3) and transcription factor JunD to promote breast cancer cell growth [31] . KRT6B interacts with notch1 to promote renal carcinoma development [32] . Studies to elucidate the mechanisms of action of these biomarkers in NSCLC development and progression are warranted.
Lu C, et al. [33] and Tian [34] also extracted gene expression data from GEO profiles to identify DEGs between LADC and LSCC. Based on the GSE6044 and GSE50081 datasets, these groups identified 19 and 33 DEGs, respectively, that might discriminate between LADC and LSCC. However, these genes were not identified based on expression fold changes between LADC and LSCC. Fold change is important for detecting DEGs [35] [36] [37] and guiding further research [38, 39] , and our eight potential biomarkers for differentiating between LADC and LSCC were identified based on this measurement type in the GSE28571, GSE37745, GSE43580, and GSE50081 datasets. Consequently, the biomarkers reported here differ from those identified in previous studies [33, 34] . This indicates that different gene expression dataset screening methods may produce different results and the differences of molecule expression between LADC and LSCC may be far more complicated than we thought.
Previous studies have identified prognostic biomarkers in patients with LADC [10, [40] [41] [42] [43] [44] or LSCC [45] [46] [47] [48] [49] . While we did not identify any LSCC prognostic indictors, we found that high KRT6A or KRT6B levels, or low NKX2-1, SFTA3, or TMC5 levels correlated with an unfavorable prognosis in LADC patients. Of these prognostic factors, only NKX2-1, thought to be a tumor suppressor [50] , was previously associated with LADC prognosis [26, 51] . The prognostic values of KRT6A, KRT6B, SFTA3, and TMC5 in LADC are reported here for the first time. Both KRT6A and KRT6B are type II cytokeratins and keratin 6 isoforms [52, 53] . KRT6A and KRT6B are associated with pachyonychia congenita [54, 55] , as well as renal carcinoma [32] and breast cancer [56] progression. SFTA3 is an immunoregulatory protein that protects lung tissue during inflammation and is likely a lung surfactant protein family member [57] . SFTA3 is also [58] . TMC5 is a transmembrane protein with at least eight membrane-spanning domains that belongs to a novel group of transporters, ion channels, or modifiers of such [59] . TMC5 is upregulated in chromophobe renal cell carcinoma [60] and intrahepatic cholangiocarcinoma [61] .
In conclusion, we identified DSG3, KRT5, KRT6A, KRT6B, NKX2-1, SFTA2, SFTA3, and TMC5 as potential biomarkers for distinguishing between LADC and LSCC. Additionally, high KRT6A or KRT6B levels, or low NKX2-1, SFTA3, or TMC5 levels correlated with unfavorable LDAC patient prognosis. Further studies are required to verify our findings in additional patient samples, and to elucidate the mechanisms of action of these potential biomarkers in NSCLC.
MATERIALS AND METHODS
Gene expression omnibus datasets
The Gene Expression Omnibus (GEO) (https:// www.ncbi.nlm.nih.gov/gds) is a public repository at the National Center of Biotechnology Information for storing high throughput gene expression datasets. We screened potential GEO datasets according to the following inclusion criteria: 1) Homo sapiens NSCLC specimens classified as LADC or LSCC; 2) expression profiling by array; 3) performed on the GPL570 platform ([HGU133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array); and 4) ≥100 samples. Datasets with specimens from other organisms, expression profiling by RT-PCR (or genome variation profiling by SNP array/SNP genotyping by SNP array), analyses on platforms other than GPL570, or sample size <100 were excluded.
We [Description] )," to identify potential datasets within GEO. Screening using the aforementioned inclusion criteria identified four datasets (GSE28571, GSE37745, GSE43580, and GSE50081) for use in analyses of DEGs between LADC and LSCC. These datasets contained 361 LADC (50 in GSE28571, 106 in GSE37745, 77 in GSE43580, and 128 in GS50081) and 210 LSCC (28 in GSE28571, 66 in GSE37745, 73 in GSE43580, and 43 in GSE50081) fresh-frozen specimens (Tables S11-S14).
Gene-cloud of biotechnology information
Gene-Cloud of Biotechnology Information (GCBI; https://www.gcbi.com.cn/gclib/html/index), is an online comprehensive bioinformatics analysis platform that can systematically analyze GEO dataset-derived gene expression information [62] . After flagged data normalization, filtering, and quality control, we identified genes differentially expressed by >5 fold between LADC and LSCC, with the cutoff values P<0.05 and Q<0.05 using GCBI.
Prognoscan
The PrognoScan (http://www.prognoscan.org/) online database provides a powerful platform for exploring therapeutic targets, tumor markers, and prognostic factors in cancer patients [63] , and contains cancer microarray datasets with corresponding clinical data. PrognoScan automatically calculates HRs, 95% CIs, and Cox P-values according to a given gene's mRNA level (high or low).
Kaplan-meier plotter
Kaplan-Meier Plotter (http://kmplot.com/analysis/) is an online database of published microarray datasets for four cancer types (breast, ovarian, lung, and gastric cancer), and includes clinical data and gene expression information for 2,437 lung cancer patients [64] . KaplanMeier Plotter is useful for assessing new biomarkers related to lung cancer patient survival.
Receiver operating characteristic curve analyses
Receiver operating characteristic (ROC) curves were constructed to compare biomarker diagnostic values. Curves are created by plotting true positive rates (TPR, sensitivity) against false positive rates (FPR, 1-specificity). The area under the curve (AUC) is used to determine diagnostic accuracy. An AUC value close to 1.0 indicates high accuracy [65] .
